Concord Drugs Ltd (CONCORD) — shareholding pattern, promoter holding, financials and share price
About Concord Drugs Ltd (CONCORD)
Concord Drugs Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as CONCORD and on the BSE under scrip code 538965. Its ISIN is INE858L01010.
Incorporated in 1995, Concord Drugs Ltd manufactures licensed drugs based on approved formulations
Concord Drugs Limited is a prominent pharmaceutical company in India, established in 1995, focusing on manufacturing various pharmaceutical formulations including injectables, tablets, and capsules.
The company operates two government-licensed manufacturing facilities equipped with advanced technology to ensure high-quality pharmaceutical production standards.
Listed peers in Pharmaceuticals: Denis Chem Lab Ltd, Vaishali Pharma Ltd, Mercury Laboratories Ltd, Makers Laboratories Ltd, Amwill Health Care Ltd, Curis Lifesciences Ltd.
Valuation & Returns
10 Jul 2026At ₹70.8 a share on 10 Jul 2026, Concord Drugs Ltd (CONCORD) was valued at a price-to-earnings ratio of 88x against an industry P/E of 36.41x and a price-to-book of 2.73x on a book value of ₹25.89 per share as of Mar 2025. Solomo computes return on equity of 3.11% and return on capital employed of 6.24% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 88x
- Industry P/E
- 36.41x
- P/B
- 2.73x
- EPS (TTM)
- ₹0.8
- Book value / share
- ₹25.89
- ROE
- 3.11%
- ROCE
- 6.24%
- ROA
- 1.63%
- Debt / equity
- 0.5x
- Dividend yield
- 0%
- EBITDA margin
- 5.79%
- 52-week range
- ₹49 – ₹92.52
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Concord Drugs Ltd (CONCORD) reported revenue of ₹78.77 crore, net profit of ₹1.06 crore and earnings per share of ₹0.8. That compares with revenue of ₹45.24 crore and net profit of ₹0.34 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹37.9 crore and net profit ₹0.53 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 58.96 | 52.08 | 44.92 | 45.24 | 78.77 |
| Net profit (₹ cr) | 1.59 | 0.99 | 0.47 | 0.34 | 1.06 |
| EPS (₹) | 1.82 | 1.06 | 0.47 | 0.34 | 0.8 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | -3.46% | -6.38% | -14.44% | 0.71% |
| Profit growth | -17.92% | -2.07% | -42.97% | -27.66% |
| Stock price CAGR | 1% | 18% | 37% | 12% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 45.08% of Concord Drugs Ltd (CONCORD) (down 9.31 pp QoQ). Market capitalisation was ₹93 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Dec 2014.
Largest disclosed public shareholders in Jun 2026: C SUSHMITHA 8.35%, ANJANA BANGAD 2.28%, ANURADHA BANGAD 2.28%, PRANALI BANGAD 2.28%, VIKAS BANGAD 2.28%, KOMAL SHARMA 1.57%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 45.08% | - | - | - | 54.92% |
| Mar 2026 | 54.39% | - | - | - | 45.61% |
| Dec 2025 | 54.39% | - | - | - | 45.61% |
| Sep 2025 | 45.08% | - | - | - | 54.92% |
| Jun 2025 | 54.39% | - | - | - | 45.61% |
| Mar 2025 | 54.39% | - | - | - | 45.61% |
| Dec 2024 | 54.39% | - | - | - | 45.61% |
| Sep 2024 | 54.39% | - | - | - | 45.61% |